Jonathan Friedberg, MD, MMSc, has been appointed Director of the James P. Wilmot Cancer Center at the University of Rochester Medical Center in New York. Dr. Friedberg joined the Medical Center in 2002 and was named Chief of the Division of Hematology/Oncology in the Department of Medicine in 2009. He has served as Acting Director of the Wilmot Cancer Center since July 2012.
“Our scientific understanding of cancer – of how it begins in our cells, how it progresses, and how we can stop it – has increased dramatically over the last decade,” said Dr. Friedberg. “Wilmot’s greatest strength is that we have clinicians and researchers working together, studying cancer and applying the latest scientific knowledge to the care of every patient. One of my goals for Wilmot is to create an environment that nurtures those interactions so that we deliver the highest quality of care for our patients.”
Dr. Friedberg is a clinical researcher whose work focuses on development of novel therapies for patients with lymphoma. He is a member of the lymphoma committee in the Southwest Oncology Group, and has served as principal investigator on many clinical trials for Hodgkin lymphoma and non-Hodgkin’s lymphoma. Dr. Friedberg earned his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed medical oncology and hematology fellowships at Dana-Farber/Partners Cancer Care. He earned an MMSC degree in clinical investigation from Harvard Medical School.
“Jonathan is respected across the institution as an academic and clinical leader of exceptional vision and talent,” said Bradford C. Berk, MD, PhD, Chief Executive Officer of the University of Rochester Medical Center. “He leads with warmth and respect for those around him, while at the same time driving multiple initiatives forward at a rapid pace. I have no doubt that Wilmot›s broad mission, that is, to deliver the most advanced cancer care, to expand the reach of our services regionally, and to be a leader in cancer research, will thrive under Jonathan’s leadership.” ■
